Sense Proteomic Ltd - Acquired by Oxford Gene Technology
Sense Proteomic is engaged in the discovery of disease-specific biomarkers based on its innovative functional protein array technology. It has identified biomarker panels for several diseases including prostate cancer and systemic lupus erythematosus, and has other biomarker discovery programmes in progress.
Oxford Gene Technology acquired Sense Proteomic in March 2009, further strengthening its mission to provide advanced genomic solutions and innovative molecular diagnostics.